Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA...
Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA...
Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA 2024 Conference
Penumbra将在VIVA 2024年会议上展示新的晚期数据，显示接受计算机辅助抽真空血栓切除技术治疗肺栓塞的患者，与其他治疗期权相比，住院时间更短，并发症更少。
- Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference
- Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system
- 数据首次在Vascular Interventional Advances（VIVA）2024年会议上展示。
- 研究结果进一步强调了计算机辅助抽真空血栓切除对患者和整体卫生系统的临床、卫生经济和成本效益。
ALAMEDA, Calif., Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study was presented this week at the Vascular Interventional Advances (VIVA) 2024 Conference.
加利福尼亚州阿拉米达，2024年11月5日/ PRNewswire / - 美国Penumbra, Inc.（纽交所：PEN），全球领先的血栓切除公司，宣布新数据显示，接受Penumbra的计算机辅助抽真空血栓切除（CAVT）技术治疗中危肺栓塞（PE）的患者，住院时间更短，术后住院时间更短，并发症更少，与其他治疗期权相比。此外，在CAVT中住院死亡率低，各治疗期权之间没有显著差异。此项晚期研究于Vascular Interventional Advances（VIVA）2024年会议上展示。
